Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (Nasdaq: NKTX) is a pioneering clinical-stage biotechnology company located in South San Francisco, California. Founded in 2015, Nkarta leverages proprietary natural killer (NK) cell expansion and engineering technologies to develop next-generation immunotherapies for the treatment of cancer and autoimmune diseases. The company’s mission is to harness the innate power of NK cells, which are the body's first line of defense, to create treatments that are more potent, better tolerated, and readily available to a broad patient population.
The core focus of Nkarta lies in its two lead candidates, NKX101 and NKX019. NKX101 is an off-the-shelf immunotherapy that targets NKG2D ligands on tumor cells, using engineered NK cells derived from healthy donors. This candidate shows promising results in treating acute myeloid leukemia (AML), with complete responses observed in high-risk patients. NKX019 targets CD19, a biomarker for B cell malignancies and autoimmune diseases such as lupus nephritis. This candidate has been designed to provide enhanced tumor cell targeting and greater persistence and activity.
Nkata's technological platform combines NK cell expansion and cryopreservation with advanced cell engineering techniques, including CRISPR-based genome engineering. This ensures a robust supply of NK cells and enables precise modification for enhanced therapeutic effectiveness. The company's cell therapies aim to be accessible for broad outpatient treatment, offering off-the-shelf solutions that minimize patient burden and reduce treatment delays.
Recent milestones include the clearance of an Investigational New Drug (IND) application by the U.S. FDA to evaluate NKX019 for lupus nephritis, expansion of their pipeline into autoimmune diseases, and strategic financial moves to extend their cash runway into 2026. Nkarta continues to provide updates on its clinical programs and looks forward to presenting additional data throughout 2024.
The company's financial backing comes from prominent investors such as SR One, NEA, and Novo Ventures, which underscores confidence in Nkarta's potential to revolutionize cell therapy. With a commitment to rigorous clinical development and strategic resource allocation, Nkarta is well-positioned to advance its innovative cell therapy candidates and deliver transformative treatments to patients in need.
Nkarta, Inc. announced its first-quarter 2021 financial results, reporting a net loss of $19.4 million, or $0.59 per share. The company has cash and equivalents of $299.7 million, projected to support operations through at least mid-2023. Key developments include FDA clearance for NKX019, a CAR NK cell therapy targeting CD19, with patient dosing expected to begin in the second half of 2021. Additionally, amendments to the NKX101 trial will streamline patient enrollment and treatment. Nkarta is collaborating with CRISPR Therapeutics to advance its cell therapy pipeline.
Nkarta, Inc. (Nasdaq: NKTX) announced that the FDA has cleared its Investigational New Drug application for NKX019, a new CAR NK cell therapy targeting CD19 in patients with relapsed or refractory B cell malignancies. This marks the company’s second IND clearance within ten months. NKX019 is designed to enhance NK cell proliferation and activity using a membrane-bound form of IL-15. The Phase 1 clinical trial for NKX019 is set to begin in the second half of 2021, reinforcing Nkarta’s commitment to developing innovative cancer therapies derived from healthy donors.
Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and FY 2020, highlighting a cash position of $315.3 million as of December 31, 2020. The company is advancing its CAR NK cell therapies, with interim clinical data for NKX101 expected by year-end 2021 and an IND application for NKX019 planned for Q1 2021. R&D expenses totaled $36.2 million for 2020, while the net loss reached $91.4 million, or $5.44 per share. Nkarta anticipates sufficient cash to sustain operations into at least mid-2023.
Nkarta, Inc. (Nasdaq: NKTX) has announced its participation in several upcoming investor conferences, highlighting its focus on advancing NK cell therapies for cancer treatment. The events include the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, featuring a fireside chat at 1:40 p.m. ET, and the Cowen 41st Annual Health Care Conference on March 3-4, 2021, with no presentation scheduled. Additionally, Nkarta will present at the Barclays Global Healthcare Conference on March 11, 2021, at 10:20 a.m. ET. Live webcasts of these presentations will be available on their website.
Nkarta, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial of NKX101, targeting acute myeloid leukemia and myelodysplastic syndromes. The company ended Q3 2020 with $330.2 million in cash, sufficient to fund operations through at least mid-2023. Nkarta plans to file an IND application for NKX019 in Q1 2021, focusing on B-cell malignancies. The Q3 financials revealed a net loss of $13.7 million, or $0.44 per share, alongside R&D expenses of $9.8 million and G&A expenses of $3.9 million.
Nkarta (Nasdaq: NKTX) has initiated its first-in-human Phase 1 clinical trial of NKX101 for treating relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). This multi-center trial aims to evaluate safety and preliminary anti-tumor activity. NKX101 is engineered to enhance natural killer (NK) cell response by targeting NKG2D, improving cytotoxic activity significantly in preclinical models. The trial addresses a critical need for effective treatments in AML patients, who have limited options and poor outcomes.
Nkarta, Inc. (Nasdaq: NKTX) has provided a preclinical update on NKX019, an investigational allogeneic cancer immunotherapy focused on treating B cell malignancies. The findings, presented at the SITC 35th Annual Meeting, indicate that NKX019 showed strong anti-tumor activity against CD19-expressing cancer models, outperforming non-engineered NK cells and demonstrating advantages over CAR T cells. Notably, NKX019 displayed reduced cytokine release syndrome risk, suggesting a favorable safety profile. Nkarta plans to file an IND application for NKX019 in Q1 2021 and initiate a Phase 1 trial for advanced B cell malignancies.
Nkarta, a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer, has announced its participation in several upcoming investor conferences.
The events include:
- Cowen 2020 IO Next Summit on November 13, 2020, at 11:45 a.m. ET
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 2:00 p.m. ET
- Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 9:40 a.m. ET
Audio webcasts will be available on Nkarta's website, with replays archived for about four weeks.
Nadir Mahmood, Ph.D. has been appointed as Chief Financial and Business Officer of Nkarta, Inc. (NASDAQ: NKTX), succeeding Matthew Plunkett, who stepped down to pursue other opportunities. Mahmood has been with Nkarta since 2018, contributing significantly to the company's strategy and operations. Alicia J. Hager, J.D., Ph.D. will join as Chief Legal Officer. Both leaders are expected to enhance Nkarta’s growth in developing engineered NK cell therapies for cancer.
Nkarta, Inc. (Nasdaq: NKTX) will participate in the Cantor Virtual Global Healthcare Conference on September 15, 2020, with a fireside chat presentation scheduled for 2:00 p.m. ET. The event will feature a live audio webcast available on Nkarta's website, with a replay archived for approximately four weeks.
Nkarta is focused on developing engineered natural killer (NK) cell therapies for cancer, utilizing a proprietary platform for efficient manufacturing and cell engineering aimed at enhancing tumor targeting and persistence.
FAQ
What is the current stock price of Nkarta (NKTX)?
What is the market cap of Nkarta (NKTX)?
What does Nkarta, Inc. specialize in?
Where is Nkarta, Inc. located?
What are Nkarta's lead therapy candidates?
How does Nkarta source its NK cells?
What are the recent achievements of Nkarta?
Who are some of Nkarta's investors?
How does Nkarta ensure its therapies are readily available?
What is the focus of Nkarta's NKX019 therapy?
What technological platforms does Nkarta use?
What future updates is Nkarta expected to provide?
